Scarica l'app Stockscreener
1.045
3.47%
0.035
Dopo l'orario di chiusura:
1.05
0.005
+0.48%
Xortx Therapeutics Inc Borsa (XRTX) Ultime notizie
XORTX Therapeutics Delays Yearly Report Filing - TipRanks
XORTX Therapeutics Higher in U.S. Pre-market Trading, Says FDA Type B Meeting Positive - marketscreener.com
XORTX Advances NDA Filing for Gout Treatment Following FDA Guidance - TipRanks
XORTX Therapeutics Provides Update On FDA Type B Meeting Request - marketscreener.com
XORTX Therapeutics Brief: Providing Update on FDA Type B Meeting Request - marketscreener.com
XORTX Provides Update on FDA Type B Meeting Request - GlobeNewswire
XORTX Therapeutics Inc. Provides Update on FDA Type B Meeting Request - marketscreener.com
XORTX Therapeutics Inc. Announces Grant of European Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease Programs - marketscreener.com
XORTX Secures European Patent for Gout and Kidney Disease Therapies - TipRanks
XORTX Announces Grant of European Patent - GlobeNewswire
XORTX Secures Game-Changing European Patent for Gout and Kidney Disease Treatments - Stock Titan
XORTX Therapeutics receives Nasdaq notice for non-compliance - MSN
XORTX Therapeutics (XRTX) Faces Nasdaq Compliance Challenge - GuruFocus
XORTX Receives Nasdaq Notification for Minimum Bid Price Deficiency - MSN
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - GlobeNewswire
XORTX Faces Nasdaq Price Compliance Challenge: 180 Days to Avoid Delisting Risk - Stock Titan
XORTX Therapeutics: Stocks Undervalued by Analyst Consensus on TSX-V (XRTX) - The Globe and Mail
1 Defense Stock to Buy for Protection During These Uncertain Times - The Globe and Mail
XORTX Therapeutics Releases Annual Information Form for 2024 - TipRanks
XORTX Therapeutics Faces Financial Challenges Amidst Operational Losses - TipRanks
XORTX Announces Update for Discussion with the FDA - GlobeNewswire
XORTX Therapeutics Announces Type B Meeting With FDA -March 19, 2025 at 07:56 am EDT - Marketscreener.com
XORTX Advances Gout Treatment Program with FDA Discussions - TipRanks
XORTX Therapeutics Brief: Announced Update for Discussion with the FDA -March 19, 2025 at 07:14 am EDT - Marketscreener.com
XORTX Announces Update For Discussion With The FDA -March 19, 2025 at 07:05 am EDT - Marketscreener.com
XORTX Advances Revolutionary Gout Treatment Toward FDA Review - StockTitan
Dr. Allen Davidoff, XORTX Therapeutics: Developing Novel Therapies for Progressive Kidney Disease - DocWire News
XORTX Starts Gout Program New Drug Application Talks With FDA -February 24, 2025 at 08:04 am EST - Marketscreener.com
XORTX Advances Gout Treatment Program with FDA Meeting Request - TipRanks
XORTX Commences Gout Program NDA Discussions with the FDA - GlobeNewswire
Can This New Gout Treatment Reach FDA Approval? XORTX Reveals Critical Timeline - StockTitan
XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial - br.ADVFN.com
XORTX to Present at Microcap Conference - GlobeNewswire
XORTX Therapeutics Engages Investors at Microcap Conference - TipRanks
Revolutionary Gout Treatment Developer XORTX Reveals Game-Changing Pipeline Updates - StockTitan
XRTXXortx Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
XORTX Therapeutics Announces Auditor Transition - MSN
XORTX Announces Change of Auditor - TipRanks
XORTX Therapeutics Appoints New Auditor to Enhance Financial Oversight - TipRanks
XORTX Therapeutics Announces Auditor Change to Davidson & Company LLP - StockTitan
XORTX Therapeutics Inc (NASDAQ:XRTX) Plunging -39.23% In 6 Months – Here’s What To Expect - Marketing Sentinel
Now Is The Time To Build A Position In XORTX Therapeutics Inc (NASDAQ:XRTX) - Marketing Sentinel
XORTX Therapeutics Expands Pipeline with Late-Stage Gout Program - TipRanks
XORTX Adds Late Stage Gout Program to Pipeline - GlobeNewswire
XORTX Launches XRx-026 Program for Allopurinol-Intolerant Gout Patients, Targets FDA Approval - StockTitan
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):